Nautilus Biotechnology Inc
NASDAQ:NAUT
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Nautilus Biotechnology Inc
Accrued Liabilities
Nautilus Biotechnology Inc
Accrued Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Accrued Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Nautilus Biotechnology Inc
NASDAQ:NAUT
|
Accrued Liabilities
$7m
|
CAGR 3-Years
8%
|
CAGR 5-Years
23%
|
CAGR 10-Years
N/A
|
|
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
Accrued Liabilities
$5.3B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
5%
|
CAGR 10-Years
12%
|
|
|
Danaher Corp
NYSE:DHR
|
Accrued Liabilities
$3B
|
CAGR 3-Years
0%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
-1%
|
|
|
Waters Corp
NYSE:WAT
|
Accrued Liabilities
$143m
|
CAGR 3-Years
0%
|
CAGR 5-Years
5%
|
CAGR 10-Years
8%
|
|
|
Agilent Technologies Inc
NYSE:A
|
Accrued Liabilities
$646m
|
CAGR 3-Years
0%
|
CAGR 5-Years
3%
|
CAGR 10-Years
7%
|
|
|
IQVIA Holdings Inc
NYSE:IQV
|
Accrued Liabilities
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Nautilus Biotechnology Inc
Glance View
Nautilus Biotechnology, Inc. operates as a life sciences company. The company is headquartered in Seattle, Washington and currently employs 113 full-time employees. The company went IPO on 2020-08-07. The firm is engaged in creating a platform technology for quantifying and unlocking the complexity of the human proteome. The firm focused on transforming the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. Its platform end-to-end solution comprised of the proteome analysis system, consumables, and software. The firm is developing a prototype of a single-molecule instrument, Proteomic Analysis System. The Company’s Proteomic Analysis Platform leverages a nanofabricated, single-molecule protein array, multi-cycle imaging, and machine learning analysis to identify and measure the proteome with sensitivity and scale.
See Also
What is Nautilus Biotechnology Inc's Accrued Liabilities?
Accrued Liabilities
7m
USD
Based on the financial report for Dec 31, 2025, Nautilus Biotechnology Inc's Accrued Liabilities amounts to 7m USD.
What is Nautilus Biotechnology Inc's Accrued Liabilities growth rate?
Accrued Liabilities CAGR 5Y
23%
Over the last year, the Accrued Liabilities growth was 5%. The average annual Accrued Liabilities growth rates for Nautilus Biotechnology Inc have been 8% over the past three years , 23% over the past five years .
